Jared Lunceford - Researcher Profile

Publications

4 shown

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon , Naiyer A. Rizvi , Rina Hui +24 more

Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer. PD-L1 expression in at least 50% of tumor...

2015 New England Journal of Medicine 6054 citations

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert , Barbara Burtness , Ranee Mehra +9 more

2016 The Lancet Oncology 1684 citations

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Kei Muro , Hyun Cheol Chung , Veena Shankaran +15 more

2016 The Lancet Oncology 1096 citations

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu , Robin Mogg , Mark Ayers +21 more

Mining immunotherapy clinical trials Clinical trial data can provide a wealth of information about how drugs work. Yet such information often belongs to pharmaceutical companies...

2018 Science 2202 citations

Frequent Co-Authors

Researcher Info

h-index: 4
Publications: 4
Citations: 11,036
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-8120-2277

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.